JAM-A and ALCAM are therapeutic targets to inhibit diapedesis across the BBB of CD14+CD16+ monocytes in HIV-infected individuals

Dionna W. Williams, Kathryn Anastos, Susan Morgello, Joan W. Berman

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'JAM-A and ALCAM are therapeutic targets to inhibit diapedesis across the BBB of CD14+CD16+ monocytes in HIV-infected individuals'. Together they form a unique fingerprint.

Medicine & Life Sciences